Overall PFS and OS results in early- and advanced-stage HL in response-adapted NCRI RAPID¹  and RATHL²  trials. (A) PFS in intention-to-treat analysis and (B) OS among interim PET-negative patients in the NCRI RAPID trial. (C) PFS and (D) OS for the whole population in the RATHL trial.